Clincosm LogoSign in Get a demo

In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma

Sponsor
The Third Xiangya Hospital of Central South University (Other)
Overall Status
Unknown status
CT.gov ID
NCT02759536
Collaborator
Beijing Capture Technology Co., Ltd (Other)
30
Enrollment
1
Location
1
Arm

Study Details

Study Description

Brief Summary

Boron Neutron Capture Therapy (BNCT) has been used in the treatment of several types of malignant tumors, including malignant melanoma, high-grade gliomas, and advanced head and neck cancers. Theoretically, it represents a more precise radiotherapy in that it could spare normal cells while destroy malignant ones. However, its value is largely restricted by the fact that it could only be performed in the nuclear research reactors, the only neutron source at the time. In 2010, the world's first in-hospital neutron irradiator (IHNI) had been constructed in Beijing, China, and this study aims to evaluate whether IHNI has the potential to serve as an effective in-hospital neutron source for BNCT.

Condition or Disease Intervention/Treatment Phase
  • Radiation: Boronophenylalanine and IHNI-based BNCT
 Phase 1/Phase 2

Detailed Description

This is a single BNCT-facility, non-randomized, non-comparative, open-label, phase I to II clinical trial to determine the value of IHNI in the performance of BNCT. Before patients are recruited in this study, they must have been confirmed as malignant melanoma by biopsy and pathological analysis. Then they will receive a boron bio-distribution test, only patients whose boron concentration in tumor tissue is >1.5 times that in the blood will be enrolled. Before patients being irradiated in IHNI, they will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes, and then blood will be withdrawn from the patient at different time points to measure boron concentration. The start point and duration of irradiation will be determined based on the boron concentration in blood and the boron bio-distribution curve.

IHNI locates in Fangshan District, Beijing, China. The recruitment of patients, and their evaluation and medical care before and after BNCT will be done in the Third Xiangya Hospital, Changsha, China.

All patients will be evaluated for response by biopsy and pathological analysis, Positron Emission Computed Tomography (PET-CT), Computed Tomography (CT) or magnetic resonance imaging (MRI).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma: A Feasibility Study
Study Start Date :
Jul 1, 2013
Anticipated Primary Completion Date :
Dec 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Boronophenylalanine and IHNI-based BNCT

Radiation: Boronophenylalanine and IHNI-based BNCT
Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.

Outcome Measures

Primary Outcome Measures

  1. Percentage of participants showing CR/PR to IHNI-based BNCT [baseline and 2 years]

    CT scan will be performed on each patient before and 2 years after irradiation, up to a maximum of 2 lesions of the longest diameter (unit: millimeter, mm) will be selected as target lesion(s). The diameter of the targeted lesion(s) will be measured on CT images. The change in the diameter of the targeted lesion(s) will be used to evaluate the patient's treatment response to IHNI-based BNCT according to Response Evaluation Criteria in Solid Tumors (RECIST). RECIST consists of four types of response: complete response (CR), partial response (PR), Stable Disease (SD), and Progressive Disease (PD). The percentage of participants who show CR/PR will be used to evaluate the efficiency of IHNI-based BNCT.

Secondary Outcome Measures

  1. Percentage of participants with treatment-related adverse events [1 week, 1 month, 3 months, 6 months, 1 year and 2 years]

    Physical examination, biochemical profile, routine blood test, and urine analysis will be performed on each patient at 1 week, 1 month, 3 months, 6 months, 1 year and 2 years after irradiation. All these results will be used to assess the grade of treatment-related adverse events according to Acute Radiation Morbidity Scoring Criteria and Late Radiation Morbidity Scoring Scheme from the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). The percentage of adverse event at each grade will be used for the evaluation of the safety of IHNI-based BNCT.

Other Outcome Measures

  1. Percentage of participants of improved life quality. [baseline and 1 year]

    This is to understand whether patients' life quality will be improved by BNCT, based on the Karnofsky performance status (KPS) score (unit: percentage, %) before and 1 year after irradiation. Questionnaires will be given to each patient at these two time points. The increase in KPS score after irradiation will be regarded as a reflection of improved life quality, and the percentage of participants who show improved life quality will be used to evaluate of benefits of IHNI-based BNCT.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Sign an informed consent form.

  2. Age above 18, gender unlimited.

  3. Expectation of life above 3 months.

  4. Characteristic of disease: ① Pathological analysis confirms the diagnosis of melanoma. ② PET-CT and serum lactate dehydrogenase (LDH) can be used for auxiliary diagnosis. ③Diameter of at least one solid tumor ≥ 1cm.

  5. KPS score: ≥70%.

  6. Eastern Cooperative Oncology Group (ECOG) score: 0-2 grade.

  7. (Within a week) Complete blood count: hemoglobin≥90g/L, leukocyte ≥ 4.0×109/L, neutrophilic granulocyte ≥ 2.0×109/L, platelet ≥ 100.0×109/L; Renal function: creatinine ≤ 180 umol/L.

  8. Never accepted radiation or chemotherapy, or the interval of radiation or chemotherapy administered above 3 month.

  9. Never accepted target drugs or biotherapeutics.

  10. Urine pregnancy test negative (selectivity).

Exclusion Criteria:

  1. Intolerable to BNCT treatment.

  2. Sever coagulation disorders.

  3. Poor compliance.

  4. Sever complications or infection without control.

  5. Pregnant woman or woman in lactation period.

  6. Patients with metallic instruments (such as pacemaker, artificial limb).

  7. Boron concentration in tumor tissue was <1.5 times that in blood.

  8. Age<18.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Third Xiangya Hospital of Central South University Changsha Hunan China 410013

Sponsors and Collaborators

  • The Third Xiangya Hospital of Central South University
  • Beijing Capture Technology Co., Ltd

Investigators

  • Principal Investigator: Shaihong Zhu, M.D., The Third Xiangya Hospital of Central South University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
The Third Xiangya Hospital of Central South University
ClinicalTrials.gov Identifier:
NCT02759536
Other Study ID Numbers:
  • XY3-IHNI1307A01
First Posted:
May 3, 2016
Last Update Posted:
Jun 7, 2016
Last Verified:
Apr 1, 2016
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Additional relevant MeSH terms:
Melanoma

Study Results

No Results Posted as of Jun 7, 2016